Only 1 in 10 Diabetes Trials Focuses on Prevention: Study

Tuesday, 09 Apr 2013 11:45 AM

By Nick Tate

  Comment  |
   Contact  |
  Print  
|  A   A  
  Copy Shortlink
Nearly two-thirds of diabetes research projects now underway around the world are focused on drug therapies and very few aim to evaluate preventive or behavioral measures to combat the disease, new research shows.
 
The study, by Duke University Medical Center scientists, found only one in 10 diabetes trials worldwide is centered on prevention or behavioral techniques. What’s more, new diabetes research tends to exclude children and older people who have much to gain from better disease management, according to the study published in Diabetologia, the journal of the European Association for the Study of Diabetes.
 
“Recently registered diabetes trials may not sufficiently address important diabetes care issues or involve affected populations,” said lead researcher Jennifer Green, M.D., of Duke University Medical Center. “Although many trials will provide valuable information upon completion, our review suggests that the current portfolio does not adequately address disease prevention, management, or therapeutic safety. This information may be meaningful in the allocation of future research activities and resources."
 
ALERT: Reverse Type 2 Diabetes. New Strategies Show How.

An estimated 371 million people have diabetes worldwide — a figure projected to grow to 550 million by 2030. To examine whether current studies adequately address the growing need for diabetes care and management, Green and colleagues analyzed nearly 2,500 diabetes-related trials registered with ClinicalTrials.gov since 2007.
 
The results of the analysis showed 75 percent were primarily focused on treatment and just 10 percent were preventive. About 63 percent involved drug therapies and only 12 percent aimed to evaluate behavioral strategies to manage the disease. Only a small percentage — 4 percent — targeted children and teens, while fewer than 1 percent targeted seniors.
 
"To achieve the greatest impact upon clinical care, trials should enroll patients representative of populations disproportionately affected by diabetes and its complications,” Dr. Green said. “A better understanding of responses to interventions among diverse individuals and groups may inform individualized treatments of greater effectiveness and tolerability."

© 2014 NewsmaxHealth. All rights reserved.

  Comment  |
   Contact  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

A-Fib Found to Double 'Silent' Stroke Risk

Monday, 24 Nov 2014 14:14 PM

Atrial fibrillation, a common condition in which the heart beats irregularly, more than doubles the risk of "silent stro . . .

Drug to Treat Hemophilia

Friday, 24 Oct 2014 12:48 PM

Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleedin . . .

4 Things You Need to Know About This Year's Flu Shot

Thursday, 04 Sep 2014 10:58 AM

At this point, scientists say they can't predict the severity of the coming flu season. But if you are planning to get t . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved